4//SEC Filing
BARKER DAVID L 4
Accession 0000950170-25-027089
CIK 0001850906other
Filed
Feb 24, 7:00 PM ET
Accepted
Feb 25, 8:01 PM ET
Size
16.0 KB
Accession
0000950170-25-027089
Insider Transaction Report
Form 4
BARKER DAVID L
Director
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2025-02-21−1,541→ 0 totalExercise: $85.80Exp: 2032-05-26→ Common Stock (1,541 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-02-21−2,466→ 0 totalExercise: $31.80Exp: 2033-05-25→ Common Stock (2,466 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2025-02-21$8.84/sh−2,466$21,799→ 0 totalExercise: $11.16Exp: 2034-05-29→ Common Stock (2,466 underlying) - Disposition to Issuer
Common Stock
2025-02-21−1,000,000→ 0 total(indirect: By Trust) - Disposition to Issuer
Common Stock
2025-02-21−60,000→ 0 total - Disposition to Issuer
Stock Option (Right to Buy)
2025-02-21−666→ 0 totalExercise: $672.90Exp: 2031-05-05→ Common Stock (666 underlying)
Footnotes (4)
- [F1]The shares were disposed of pursuant to the Agreement and Plan of Merger, dated as of December 22, 2024 (the "Merger Agreement"), by and among the Issuer, Singular Genomics Parent, LLC, a Delaware limited liability company, and Saturn Merger Sub, Inc., a Delaware corporation, whereby, at the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were cancelled and automatically converted into the right to receive $20.00 per share in cash, without interest, less all applicable deductions and withholdings (the "Merger Consideration").
- [F2]The Reporting Person is the trustee of The Barker/Loring Trust and has voting and dispositive power with respect to these shares.
- [F3]As of the Effective Time, each outstanding option, to the extent unvested, was accelerated and became fully vested and exercisable.
- [F4]Pursuant to the Merger Agreement, and after giving effect to the acceleration treatment set forth in footnote (4), each vested stock option was cancelled and automatically converted into the right to receive an amount in cash determined by multiplying (x) the excess, if any, of the Merger Consideration over the applicable exercise price of such option by (y) the number of vested shares subject to such option (the "Option Payment"), less all applicable deductions and withholdings; provided, however, that the Option Payment for each option with an exercise price equal to or greater than $20.00 was $0 and such option was cancelled for no consideration.
Documents
Issuer
Singular Genomics Systems, Inc.
CIK 0001850906
Entity typeother
Related Parties
1- filerCIK 0001189124
Filing Metadata
- Form type
- 4
- Filed
- Feb 24, 7:00 PM ET
- Accepted
- Feb 25, 8:01 PM ET
- Size
- 16.0 KB